No Data
KPC PharmaceuticalsInc's (SHSE:600422) Investors Will Be Pleased With Their Respectable 86% Return Over the Last Five Years
GF Securities Starts KPC Pharmaceuticals at Buy With 20.80 Yuan Price Target
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
KPC Pharmaceuticals' 2024 Profit Rises 20%
KPC Group: KPC 2024 Annual Report
KPC Group: Summary of the 2024 Annual Report of KPC
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing